Last reviewed · How we verify
NCT02408406
PatientCareAnywhere Internet-Based Software in Improving Communication and Education in Patients With Cancer and Their Healthcare Providers
NA trial testing Communication Intervention in Bladder Carcinoma in 140 participants. Completed in 19 June 2024.
19 June 2024
Quick facts
| Lead sponsor | City of Hope Medical Center |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | supportive care |
| Enrollment | 140 |
| Start date | 7 July 2015 |
| Primary completion | 19 June 2024 |
| Estimated completion | 19 June 2024 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Communication Intervention
- Educational Intervention
- Internet-Based Intervention
- Quality-of-Life Assessment
- Questionnaire Administration
Conditions studied
- Bladder Carcinoma — all drugs for Bladder Carcinoma →
- Breast Carcinoma — all drugs for Breast Carcinoma →
- Colorectal Carcinoma — all drugs for Colorectal Carcinoma →
- Lung Carcinoma — all drugs for Lung Carcinoma →
Sponsor
City of Hope Medical Center
Who can join
21 and older, any sex, with Bladder Carcinoma or Breast Carcinoma. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This partially randomized pilot clinical trial develops and studies a software program, called PatientCareAnywhere, to see whether it can help patients communicate with their doctors and other healthcare providers, and educate themselves about their cancer and treatment options. A program that can help patients learn about their cancer and treatment options, and allows the patient's healthcare providers to receive their questionnaire results, may help patients identify and get help to treat their symptoms.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Usability and Preliminary Efficacy of an Adaptive Supportive Care System for Patients With Cancer: Pilot Randomized Controlled Trial.
Baik SH, Clark K, Sanchez M, Loscalzo M, et al · · 2024 · cited 4× · PMID 38986134 · DOI 10.2196/49703
Verify or expand the search:
- PubMed search for NCT02408406
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Communication Intervention
Trials testing the same drug.
- NCT07282444 — A New Way to Share Radiation Therapy Plans Between Doctors, CORRECT Trial · NA · not yet recruiting
- NCT07504835 — GET FIT Together: Testing a Socially Enhanced Exercise Program in Older Men With Prostate Cancer · NA · not yet recruiting
- NCT04871477 — Adoption of Audio Recording in the Outpatient Supportive Care Center · not yet recruiting
- NCT07143487 — Family Communications After Genetic Testing · NA · not yet recruiting
- NCT07186530 — Offering HPV Self-Collection in Novel Healthcare Settings to Improve Uptake of Cervical Cancer Screening · NA · enrolling by invitation
Other recruiting trials for Bladder Carcinoma
Currently open trials in the same condition.
- NCT07285044 — The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Tr · Phase 2 · recruiting
- NCT07067749 — Treatment Expedition With MRI Processing and Optimization for Muscle Invasive Bladder Cancer · Phase 3 · recruiting
- NCT07118176 — Determining the Biodistribution of an Imaging Tracer (68Ga-FAPi-46) in Patients With Solid Tumors or Hematologic Cancers · Phase 1 · recruiting
- NCT06995898 — The Vanguard Study: Testing a New Way to Screen for Cancer · NA · recruiting
- NCT06891209 — Exploration of HRQOL and Urinary Outcomes Following Partial Cystectomy · recruiting
Other City of Hope Medical Center trials
Trials by the same sponsor.
- NCT07365306 — Epcoritamab, Rituximab, Gemcitabine and Oxaliplatin (R-GemOx) as Salvage Therapy Before Autologous Stem Cell Transplant · Phase 2 · not yet recruiting
- NCT07218692 — RP2 and Tivozanib for the Treatment of Metastatic Renal Cell Cancer After Progression on Immunotherapy · Phase 2 · not yet recruiting
- NCT07363408 — Ivonescimab and ADG126, Alone, and in Combination With Leucovorin and Fluorouracil or FOLFIRI Regimen for the Treatment · Phase 1 · not yet recruiting
- NCT07226102 — Virtual Mental Health Intervention to Address Fear of Progression for Women With High Risk or Stage III-IV Gynecologic o · NA · withdrawn
- NCT07225855 — Geriatric Assessment and Management for Older Adults Undergoing Chemotherapy and Radiation Therapy for Head and Neck Can · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT02408406 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by City of Hope Medical Center
- Last refreshed: 27 June 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02408406.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing